|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2008-5-16
|
|
pubmed:abstractText |
CT-011 is a humanized IgG1 monoclonal antibody that modulates the immune response through interaction with PD-1, a protein belonging to the B7 receptor family present on lymphocytes. The objectives of this phase I study were to assess the dose-limiting toxicities, to determine the maximum tolerated dose, and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematologic malignancies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3044-51
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18483370-Adult,
pubmed-meshheading:18483370-Aged,
pubmed-meshheading:18483370-Antibodies, Monoclonal,
pubmed-meshheading:18483370-Antigens, CD,
pubmed-meshheading:18483370-Antineoplastic Agents,
pubmed-meshheading:18483370-Apoptosis Regulatory Proteins,
pubmed-meshheading:18483370-Area Under Curve,
pubmed-meshheading:18483370-Dose-Response Relationship, Drug,
pubmed-meshheading:18483370-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18483370-Female,
pubmed-meshheading:18483370-Hematologic Neoplasms,
pubmed-meshheading:18483370-Humans,
pubmed-meshheading:18483370-Male,
pubmed-meshheading:18483370-Maximum Tolerated Dose,
pubmed-meshheading:18483370-Middle Aged,
pubmed-meshheading:18483370-Programmed Cell Death 1 Receptor
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
|
|
pubmed:affiliation |
Institute of Oncology and Radiotherapy, Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
